Skip to content

A New Method: the Third Space Robotic and Endoscopic Cooperative Surgery (TS-RECS)

Feasibility of the Third Space Robotic and Endoscopic Cooperative Surgery(TS-RECS) for Treating Gastric Stromal Tumor

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03804762
Enrollment
10
Registered
2019-01-15
Start date
2018-04-05
Completion date
2018-12-20
Last updated
2019-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Soft Tissue Neoplasm

Brief summary

The third space robotic and endoscopic cooperative surgery (TS-RECS) combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view. TS-RECS takes full advantage of the methodology of the third space, making it possible to dissect gastric GISTs (gastrointestinal stromal tumors) entirely without the damage of mucosal layer. Here, this study preliminarily assessed the feasibility, safety and effectivity of the novel hybrid operation.

Interventions

PROCEDUREthe third space robotic and endoscopic cooperative surgery

This technique combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view, and take full advantage of the methodology of the third space to dissect gastric submucosal tumors.

Sponsors

First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with gastric GISTs originating from muscularis propria diagnosed by EUS (endoscopic ultrasound); * The maximal cross-sectional diameter of tumor ranging from 2cm to 5cm, or the maximal cross-sectional diameter of tumor \<2cm but with malignant potential ( irregular shape, cystic space, heterogeneity and rapid growth during follow-ups ) ; * No evidence of tumor metastasis on all per-operative evaluations;

Exclusion criteria

* 1\. Patients with serious systemic comorbidities, such as severe heart failure, respiratory failure, uncontrolled hypertension; * 2\. Patients with advanced malignant tumor; * 3\. Patients were required the emergency operation by complete intestinal obstruction, perforation and hemorrhage caused by the tumor; * 4.Patients with ulcer penetration into tumors; * 5\. Patients with the contraindications for general anesthesia; * 6\. Patients were pregnant or younger than 18 years old;

Design outcomes

Primary

MeasureTime frameDescription
the rate of adverse eventsthrough study completion, an average of 6 monthsAdverse events included intraoperative adverse (full-thickness perforation, hemorrhage, injury of visceral organs and vessel, and anaesthesia complications), and postoperative adverse events (infectious complications, intra-abdominal /intraluminal bleeding, gastric stasis and leakage)

Secondary

MeasureTime frameDescription
the rate of intact mucosal layer1 dayintact mucosal layer was defined as the tumor resection without full-thickness incision caused by operation
operation time1 dayOperation time was defined from the time of docking to the time of trocar incision closure.
rate of en bloc resection1 daythe en bloc resection was defined as complete tumor resection with negative surgical margin.
time to oral diet30 daystime to oral diet to assess the postoperative course.
duration of postoperative hospital stay30 daysFrom the day of operation to the day of discharged, duration of postoperative hospital stay to assess the postoperative course.
estimated blood loss1 dayBlood loss was estimated through the analysis of the surgical and anaesthesiological reports.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026